CMPS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compass Pathways (CMPS) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including favorable analyst ratings, hedge fund buying trends, and a potential FDA approval for its flagship product. While technical indicators are neutral, the long-term growth prospects outweigh short-term uncertainties.
The MACD is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 62.362, and moving averages are converging, suggesting no clear trend. Key resistance levels are at 12.713 and 13.258, with support at 10.949 and 10.405.
Analysts have consistently raised price targets, with the most recent targets ranging from $14 to $20, reflecting optimism about the company's growth potential.
Hedge funds are buying aggressively, with a 302.54% increase in buying activity over the last quarter.
The company is on track to develop the first FDA-approved oral psychedelic drug for treatment-resistant depression, with a potential launch by year-end
The FDA's granting of a Commissioner's National Priority Voucher accelerates the commercial timeline for COMP360.
No significant insider trading trends, indicating a lack of insider confidence.
Technical indicators are neutral, providing no strong short-term entry signal.
Options data shows a high put-call volume ratio (2.31), suggesting bearish sentiment among options traders.
No financial data available for analysis. However, the company reported an operating loss of ($42.9M) in Q1 2026 and ended the period with $466M in cash, indicating sufficient liquidity to execute its growth plans.
Analysts are overwhelmingly positive, with multiple Buy ratings and price targets ranging from $14 to $20. Recent updates highlight optimism about the company's flagship product, COMP360, and its accelerated timeline for FDA approval and launch.
